Bimekizumab superior to Cosentyx in achieving complete psoriasis skin clearance. UCB
UCB announced positive results from the Phase IIIb BE RADIANT study, a direct comparison of the investigational IL-17A and IL-17F inhibitor, bimekizumab, to the IL-17A inhibitor, Cosentyx (secukinumab)… read more.